Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.195 USD | -2.59% | +3.40% | +58.17% |
May. 10 | Leerink Partners Starts Aquestive Therapeutics With Outperform Rating, $8 Price Target | MT |
May. 08 | Transcript : Aquestive Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+58.17% | 299M | |
+32.01% | 694B | |
+29.39% | 593B | |
-1.59% | 371B | |
+19.81% | 331B | |
+6.85% | 290B | |
+14.25% | 239B | |
-3.03% | 209B | |
+10.02% | 209B | |
+8.14% | 169B |
- Stock Market
- Equities
- AQST Stock
- News Aquestive Therapeutics, Inc.
- Aquestive Therapeutics Obtains FDA Approval for Libervant to Treat Seizure in Children